Laurance Smith, MD
Neurology · Blue Bell, PANPI 1225079213
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for neurology clinicians in PA, where the typical reported total is $778.
Across 19 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$89
- TG Therapeutics, Inc.$72
- Biohaven Pharmaceuticals, Inc.$32
- AstraZeneca$25
- Argenx US, Inc.$24
- SK Life Science, Inc.$23
- plus $128 from 7 others
What the payments were for
- Speaking & faculty fees$174%
- Food & beverage$37696%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $89 |
| TG Therapeutics, Inc. | 3 | $72 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| AstraZeneca | 1 | $25 |
| Argenx US, Inc. | 1 | $24 |
| SK Life Science, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| Biogen | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Acorda Therapeutics, Inc | 1 | $17 |
| UCB, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
How this compares
$393 in reported general payments places this provider in the 40th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dimethyl Fumarate | 16 | $135,114 |
| RebifInterferon Beta-1a/Albumin | 11 | $134,306 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 15 | $122,882 |
| GlatopaGlatiramer Acetate | 11 | $45,292 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,610 |
| Lamotrigine ErLamotrigine | 41 | $5,804 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 87 | $2,801 |
| Donepezil Hcl | 130 | $1,934 |
| Levetiracetam | 50 | $1,843 |
| Pregabalin | 31 | $1,644 |
| Levetiracetam ErLevetiracetam | 24 | $1,527 |
| Oxcarbazepine | 22 | $1,424 |
| Entacapone | 15 | $1,220 |
| Lamotrigine | 12 | $1,156 |
| Gabapentin | 32 | $876 |
Paid to pharmacies, not to this prescriber.
Other neurology in Blue Bell
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Ravi DukkipatiYork$936K
- Brad KleinAbington$927K
- Stephanie Nahas-GeigerPhiladelphia$786K
- John KhouryAbington$686K
- Amit Bar-OrPhiladelphia$596K
- Behrang SaminejadAllentown$594K
- Anoopum GuptaPittsburgh$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.